Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safety in rea...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC neurology Ročník 19; číslo 1; s. 159 - 9
Hlavní autoři:	Zecca, Chiara, Disanto, Giulio, Sacco, Rosaria, Riccitelli, Gianna C., Gobbi, Claudio
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 12.07.2019 BioMed Central Ltd BMC
Témata:	Biological response modifiers CIS Comorbidity Demyelinating diseases Dosage and administration Drug approval Drug therapy Glatiramer acetate Interferon Medical records Medicine Medicine & Public Health Multiple sclerosis Neurochemistry Neurology Neurosurgery Patient monitoring equipment Patient outcomes Prescription writing Relapsing remitting Research Article Therapy Switzerland Glatiramer acetate Relapsing remitting Therapy Multiple sclerosis GA CIS
ISSN:	1471-2377, 1471-2377
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!